home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

ANDA Submission and GDUFA Guidance

 
  August 11, 2020  
     
 
Compliance online, Online Event
1 October 2020


Why Should You Attend:

In addition, with the passage of GUFDA II which significantly changes the fee structure, it is also crucial to understand the major changes to the program, and the effects of those changes on the generics industry.

This webinar explains the submittal process of drugs and medicinal products and also explores the GUFDA II Guidance.

Areas Covered in the Webinar:

  • Overview of the ANDA and PAS processes
  • Overview of GDUFA
  • The FDA’s process for classifying major, minor, and unsolicited amendments to ANDAs or PASs.
  • How ANDA or PAS deficiencies that will cause the FDA to request a major amendment or classify deficiency responses as a major amendment.
  • The amendment format and submission process.
  • The FDA's review goals for amendments under GDUFA II.
  • How the FDA will process amendments submitted before GDUFA II.
  • How to request that the FDA reconsider classifying a major amendment.
  • A discussion of how high quality standards are maintained through inspections and risk-based approaches.
  • The process of and reasons for requiring the identification of the facilities involved in the manufacture of generic drugs and the associated active pharmaceutical ingredients.
  • The intent of the FDA to expedite product access.
  • How amendment submissions may affect review goal dates.

Who Will Benefit:

The audience for this webinar would consist of anyone in the generic pharma business in the following functions:

  • Compliance and regulatory,
  • Research & development,
  • Quality assurance. Positions would include – Director, Associate Director, Manager, and associates
 
 
Organized by: ComplianceOnline
Invited Speakers:
Charles H Paul

Charles H Paul
President, C H Paul Consulting Inc

Charles H. Paul is the President of C. H. Paul Consulting, Inc. – a regulatory, training, and technical documentation consulting firm. Charles is a management consultant, instructional designer and regulatory consultant and has led C. H. Paul Consulting, Inc. since its inception over 25 years ago. He regularly consults with Fortune 500 pharmaceutical, medical device, and biotechnology firms assisting them in achieving human resource, regulatory, and operational excellence. He is a regular presenter of webinars and on-site seminars in a variety of related subjects from documentation development to establishing compliant preventive maintenance systems. The firm works globally completing projects throughout the EU, UK, South America, and Asia.


 
Deadline for Abstracts: 2020-08-10
 
Registration: https://www.complianceonline.com/anda-submission-gdufa-guide-webinar-training-706538-prdw?channel=hum-molgen
E-mail: referral@complianceonline.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2020 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.